Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Energy and Commerce’s health care plans

This article was originally published in The Tan Sheet

Executive Summary

The House Energy and Commerce Committee's oversight plan for the 111th Congress includes assessing "whether necessary safeguards for imported drugs are in place," which is a focus of the FDA Globalization Act co-sponsored by former committee chairman John Dingell, D-Mich. (1"The Tan Sheet" Feb. 2, 2009, p. 6). Energy and Commerce also will examine manufacturing practices for Rx and nonprescription drugs and investigate off-label marketing of Rx drugs. House committees must submit oversight plans to the Oversight and Government Reform Committee and the House Administration Committee near the start of each session. The plans outline topics committees want to address, but the panels can narrow or expand their work during a session

You may also be interested in...



Salmonella Problem Stirs Food Safety Bills, Hearing From Energy & Commerce

At an upcoming hearing, House Energy and Commerce Committee leaders will question executives from labs that tested ingredients at the peanut processing facility linked to widespread recalls due to salmonella contamination

QUOTED. 9 April 2020. Frans van Houten.

Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.

COVID-19 Lock-Down: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Topics

UsernamePublicRestriction

Register

PS102632

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel